ResMed (RMD)

• Market cap: $34.8B
• 1 day: 2.46%
• 5 days: -0.58%
• 1 month: -1.77%
• 3 months: -3.13%
• 6 months: 11.25%
• Year to date: 38.12%
• 1 year: 36.39%
• 5 years: 52.16%
• 10 years: 317.80%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Employees: 9,980

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

67% more funds holding in top 10

Funds holding in top 10: 6 [Q2] → 10 (+4) [Q3]

32% more first-time investments, than exits

New positions opened: 108 | Existing positions closed: 82

23% more capital invested

Capital invested by funds: $17.1B [Q2] → $21.1B (+$3.94B) [Q3]

22% more repeat investments, than reductions

Existing positions increased: 312 | Existing positions reduced: 255

3% more funds holding

Funds holding: 757 [Q2] → 783 (+26) [Q3]

2.14% less ownership

Funds ownership: 60.97% [Q2] → 58.83% (-2.14%) [Q3]

59% less call options, than puts

Call options by funds: $253M | Put options by funds: $619M

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $232 2% downside
• Avg. target: $260 10% upside
• High target: $283 19% upside

5 analyst ratings

• positive: 3 60%
• neutral: 2 40%
• negative: 0 0%

Stifel Jonathan Block 22% 1-year accuracy 4 / 18 met price target	5% upside $250	Hold Initiated	13 Dec 2024
RBC Capital Craig Wong-Pan 0 / 0 met price target	2% downside $232	Sector Perform Maintained	25 Oct 2024
Keybanc Brett Fishbin 65% 1-year accuracy 13 / 20 met price target	12% upside $266	Overweight Maintained	25 Oct 2024
Baird Joe Vruwink 50% 1-year accuracy 21 / 42 met price target	19% upside $283	Outperform Maintained	25 Oct 2024
B of A Securities Lyanne Harrison 0% 1-year accuracy 0 / 1 met price target	14% upside $270	Buy Maintained	26 Sept 2024